The global cytomegalovirus treatment market is anticipated to grow at a CAGR of 30.1% during the forecast period (2023-2030). Cytomegalovirus is one of the most common and serious post-transplant infections and can lead to loss of transplanted organ and failure of graft. It has a global estimated incidence rate of 16.0%–56.0% in SOT recipients and 30.0%–70.0% in HSCT recipients.More than 34,000 SOTs and more than 48,000 HSCTs were performed in Europe and neighboring countries in 2019. Thus, the growing drug approval for its treatment is a key factor driving the growth of the global cytomegalovirus treatment market.
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/cytomegalovirus-treatment-market
For instance, in September 2022, Takeda announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).
In August 2022, Florida, US-based firm Fortress Biotech has been awarded a $20 million grant to develop its cytomegalovirus vaccine Triplex. Under development by its subsidiary Helocyte, Triplex is a universal viral vector vaccine, which has been engineered to induce a cytomegalovirus -specific T cell response. In previous Phase I and Phase II studies, it has been found to be safe, well-tolerated and immunogenic. Helocyte has secured an exclusive worldwide license to Triplex from its originator, City of Hope cancer research center.Fortress plans to test its candidate across up to 15 transplant centers in the US. Triplex was developed by City of Hope, one of the largest cancer research and treatment organizations in the US. Development of cytomegalovirus vaccine may restrain the global cytomegalovirus treatment market.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Drug Type
o By Application
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- including F. Hoffmann-La Roche Ltd, Teva Canada Ltd., Gilead Sciences, Inc., Thermo Fisher Scientific, Inc., and Merck & Co., Inc. among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Cytomegalovirus Treatment Market Report Segment
By Drug Type
- Cidofovir
- Foscarnet
- Valganciclovir
- Ganciclovir
By Application
- Stem Cell Transplantation
- Organ Transplantation
- Congenital CMV Infection
- Other Application
By Distribution Channel
- Hospital pharmacies
- Retail Pharmacies
- E-commerce
A full report of Cytomegalovirus Treatment Market available @ https://www.omrglobal.com/industry-reports/cytomegalovirus-treatment-market
Global Cytomegalovirus Treatment Market Report Segment by Region
North America
- United States
- Canada
Europe
- Germany
- United Kingdom
- France
- Spain
- Italy
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Rest of Asia-Pacific
Rest of the World
- Middle East & Africa
- Latin America
Company Profiles
· AiCuris Anti-infective Cures GmbH
· Chimerix, Inc.
· Clinigen Group PLC
· F. Hoffmann-La Roche AG
· Fresenius Kabi Canada
· Genentech Inc.
· Gilead Sciences, Inc.
· GlaxoSmithKline plc
· Merck & Co., Inc.
· Moderna, Inc.
· Mylan N.V
· Pfizer Inc.
Reasons to Buying From us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
Visit more report at